837 Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous (SC) interleukin-2 (IL-2) and interferon-alpha-2b (IFN) in metastatic melanoma

Emilio Bajetta(Fondazione Lanza), Maria Grazia Bernengo(University of Turin), Domenico Santangelo(Vita-Salute San Raffaele University), Mario Santinami(Fondazione IRCCS Istituto Nazionale dei Tumori), Luciano Gattinoni(Universitätsmedizin Göttingen), Antonio Daponte(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), M.R. Sertoli(National Cancer Research Institute), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), P. Nova(Sorbonne Université), Paola Queirolo
European Journal of Cancer Supplements
September 1, 2003
10.1016/s1359-6349(03)90863-9
Cited by 5

Related Papers

Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries
|JAMA|2016|5.9k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material
|Intensive Care Medicine|2012|1.5k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k